Navigation Links
Erlotinib dose-adjusted for smoking status effective as first treatment for head and neck cancer
Date:1/26/2012

Head and neck cancers respond well to the anti-cancer drug erlotinib when it is administered before surgery and a stronger dose is given to patients who smoke, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

Erlotinib is an oral anti-cancer drug that can slow a tumor's growth and spread by inhibiting specific growth receptors on the surface of the cancer cells. Early detection of a patient's response to EGFR inhibitors, such as erlotinib, is critical to personalizing head and neck cancer treatments.

In a first of its kind study in patients with head and neck cancer, researchers sought to determine how well tumors unaffected by other therapies respond to erlotinib, when the drug dose was adjusted according to the patient's smoking status. It has been recently shown that smokers metabolize the drug faster than nonsmokers.

Nonsmokers received 150 mg per day and smokers received 300 mg per day for at least 14 days before surgery. A FDG-PET scan and neck CT was performed before treatment and at the end of erlotinib administration. In addition, an early FDG-PET was performed after four to six days of treatment.

The results showed that erlotinib is effective as a first line of therapy when the dose is adjusted per smoking status, even when used for a limited duration. Both smokers and nonsmokers tolerated the dose of erlotinib and neither experienced serious adverse effects. The study also showed that the FDG-PET scan taken early can show changes in the standard uptake value and predict a patient's response to erlotinib.

"We hope our results will motivate clinicians to consider and investigate further the use of erlotinib in patients with head and neck cancer and adjust the dose for smoking status," Mercedes Porosnicu, MD, lead author of the study and an assistant professor of internal medicine at Wake Forest Baptist Medical Center in Winston Salem, N.C., said. "We also hope that our study will help better select the patients expected to respond to erlotinib."


'/>"/>
Contact: Nicole Napoli
nicolen@astro.org
703-839-7336
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Blood test may identify lung cancer patients likely to respond to erlotinib
2. TRUST study data confirms safety and efficacy of erlotinib for advanced lung cancer
3. Less toxic combination of erlotinib and bevacizumab is effective non-small cell lung cancer patients
4. PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumors
5. EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy
6. New Report: $1 Cigarette Tax Increase Would Raise $418.8 Million for Texas and Cut Youth Smoking
7. New Report: $1 Cigarette Tax Increase Would Raise $18.6 Million for Montana and Cut Youth Smoking
8. New Report: $1 Cigarette Tax Increase Would Raise $24.8 Million for Wyoming and Cut Youth Smoking
9. New Report: $1 Cigarette Tax Increase Would Raise $43.3 Million for Utah and Cut Youth Smoking
10. New Report: $1 Cigarette Tax Increase Would Raise $113.9 Million for Colorado and Cut Youth Smoking
11. New Report: $1 Cigarette Tax Increase Would Raise $65.3 Million for Iowa and Cut Youth Smoking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... 12th Annual ... FDAnews**, Nov. 1-3, 2017 – Bethesda, MD, http://www.fdanews.com/fdainspectionssummit , Nine times ... then, on the tenth inspection it failed. , What went wrong? , Come ...
(Date:9/24/2017)... ... 25, 2017 , ... Bhowanie Benimadhu’s new book “ Our Creative World: Our ... and seeks answers in both Eastern and Western religious traditions and spirituality such as ... the mind of humankind for the past thousands of years and still are,” Benimadhu ...
(Date:9/24/2017)... ... ... Throughout the United States and the world, clinicians take a simple but powerful ... work to give the best care possible to patients and communities, while seeking newer, ... threatening to tie our hands in carrying out that oath. The Graham-Cassidy legislation to ...
(Date:9/24/2017)... ... September 24, 2017 , ... “The Messiah 8 with the ... texts to firsthand experiences. “The Messiah 8 with the 3rd Anti Christ” is the ... I’ve tried to look at all the angles of life,” Velazquez states, “I always ...
(Date:9/24/2017)... ... 24, 2017 , ... “The Gospel Truth Of The Bible: The Other Sheep”: the ceremonial laws ... Bible: The Other Sheep” is the creation of published author, Maurice Caines. Maurice Caines ... He has been a member of the Seventh-day Adventist Church for many years. ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017  Medical ... knowledge and skills while treating their patients. ... hands-on experience without involving patients. Simulation provides ... Clinicians can carry out procedures, refine techniques ... risk. Integration of new technology, such as ...
(Date:9/5/2017)... -- Xyntek Inc. has announced another milestone in their continued growth and success of ... growing demands of customer engagements regionally.  ... Midwest office is located at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest ... In ...
(Date:9/1/2017)... , Sept. 1, 2017  Explorers Like Us ( ... America,s greatest aural experiences — and deliver these experiences as ... to help people feel and heal better. ... While nothing beats a walk, ... refresh your mind, Life Environments™ is the next best thing ...
Breaking Medicine Technology: